NCT01727908
Screening for Familial Gastric Cancer in First Degree Relatives No drug interventions prevention Not Available terminated NCT00061932
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach treatment 2 completed NCT00991952
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery treatment 2 completed NCT00064259
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer treatment 1 / 2 terminated NCT00103324
S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer treatment 2 completed NCT00028496
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer treatment 1 completed NCT01212822
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer treatment 2 completed NCT02344810
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer treatment 1 / 2 withdrawn NCT01939275
64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer No drug interventions diagnostic Not Available active_not_recruiting NCT01643499
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies treatment 1 completed NCT01231399
Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer treatment 1 / 2 completed NCT00084617
Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma treatment 2 completed NCT00084604
Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma treatment 2 completed NCT01612546
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery treatment 2 completed